The CRF peptide family and their receptors: yet more partners discovered

Abnormal signaling at corticotropin-releasing factor CRF 1 and CRF 2 receptors might contribute to the pathophysiology of stress-related disorders such as anxiety, depression and eating disorders, in addition to cardiac and inflammatory disorders. Recently, molecular characterization of CRF 1 and CR...

Full description

Saved in:
Bibliographic Details
Published in:Trends in Pharmacological Sciences 2002-02, Vol.23 (2), p.71-77
Main Authors: Dautzenberg, Frank M., Hauger, Richard L
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Animals
Corticotropin-releasing factor
Corticotropin-Releasing Hormone - metabolism
Corticotropin-Releasing Hormone - pharmacology
Corticotropin-Releasing Hormone - physiology
CRF receptor
CRF receptor antagonist
CRF receptor deficient mice
Humans
ligand selectivity
Molecular Sequence Data
Receptors, Corticotropin-Releasing Hormone - agonists
Receptors, Corticotropin-Releasing Hormone - antagonists & inhibitors
Receptors, Corticotropin-Releasing Hormone - biosynthesis
Receptors, Corticotropin-Releasing Hormone - physiology
stress-related disorders
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abnormal signaling at corticotropin-releasing factor CRF 1 and CRF 2 receptors might contribute to the pathophysiology of stress-related disorders such as anxiety, depression and eating disorders, in addition to cardiac and inflammatory disorders. Recently, molecular characterization of CRF 1 and CRF 2 receptors and the cloning of novel ligands – urocortin, stresscopin-related peptide/urocortin II, and stresscopin/urocortin III – have revealed a far-reaching physiological importance for the family of CRF peptides. Although the physiological roles of the CRF 2 receptor remain to be defined, the preclinical and clinical development of specific small-molecule antagonists of the CRF 1 receptor opens new avenues for the treatment of psychiatric and neurological disorders. The development of selective CRF1 receptor antagonists supports the hypothesis that aberrant CRF1 receptor signaling contributes to the pathophysiology of affective disorders. The recent identification of novel selective CRF2 receptor peptides will help to understand CRF2 receptor physiology.
ISSN:0165-6147
1873-3735
DOI:10.1016/S0165-6147(02)01946-6